Benjamin Brady
OhioHealth(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses
Most-Cited Works
- → Nivolumab in Previously Untreated Melanoma without BRAF Mutation(2014)5,312 cited
- → Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis(2017)625 cited
- → Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy(2018)340 cited
- → Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma(2020)219 cited
- → Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma(2017)109 cited
- → Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series(2018)91 cited
- → A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy(2010)54 cited
- → Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma(2015)53 cited
- → Nevi and Melanoma: Lessons from Turner’s Syndrome(2001)33 cited
- → Optimizing combination dabrafenib and trametinib therapy in BRAF mutation‐positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists(2016)32 cited